Register
Forgot your password?

Features of the pathogenesis of coronary heart disease in HIV infection

Authors: Murkamilov I.T., Aytbaev K.A., Fomin V.V., Schastlivenko A.I.

Company: 1 I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, 720020, Kyrgyzstan
2 Kyrgyz Russian Slavic University, Bishkek, 720000, Kyrgyzstan
3 Research Institute of Molecular Biology and Medicine, Bishkek, 720040, Kyrgyzstan
4 I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation
5 Vitebsk State Order of Peoples Friendship Medical University, Vitebsk, 210009, Belarus

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2020-14-3-255-271

For citation: Murkamilov I.T., Aytbaev K.A., Fomin V.V., Schastlivenko A.I. Features of the pathogenesis of coronary heart disease in HIV infection. Creative Cardiology. 2020; 14 (3): 255–71 (in Russ.). DOI: 10.24022/1997-3187-2020-14-3-255-271

Received / Accepted:  01.09.2020 / 07.09.2020

Keywords: human immunodeficiency virus inflammation dyslipidemia risk factors coronary heart disease

Full text:  

 

Abstract

There are currently 36.7 million people living with immunodeficiency viruses (HIV) worldwide. Every day more than 7 thousand people are infected with HIV and over 5.2 million people need antiretroviral therapy. Many researchers note that the HIV epidemic has already acquired a new quality – a large number of comorbid conditions and severe forms of cardiovascular diseases (CVD). The article presents data on high risk and early onset of CVD in people with HIV – infection compared to the general population. The effect on CVD genesis in HIVinfected patients is considered both of individual traditional and additional (specific) risk factors. The evidence of the contributing role of HIV infection in the occurrence of coronary heart disease is presented, including through pathogenetic mechanisms such as viral load, endothelial dysfunction, inflammation, and activation of the immune system. It was noted that correction of CVD risk factors for HIV infection, including viral load using antiretroviral therapy, reduces cardiovascular risk.

References

  1. Andreenko E.Yu., Yavelov I.S., Loukyanov М.М., Vernokhaeva A.N., Drapkina O.M., Boytsov S.A. Ischemic heart disease in subjects of young age: current state of the problem: Prevalence and Cardio-Vascular Risk Factors. Kardiologiia. 2018; 58 (10): 53–8. DOI: 10.18087/cardio.2018.10.10184 (in Russ.).
  2. UNAIDS. Joint United Nations Programme on HIV/AIDS. Ending AIDS: progress towards the 90-90-90 targets. Global AIDS Update. http://www.unaids.org (дата обращения 27.12.2017).
  3. Yakushin S.S., Filippov E.V. HIV infection and cardiovascular complications. The Clinician. 2011; 5 (2): 6–12. DOI: 10.17650/1818-8338-2011-2-6-12 (in Russ.).
  4. Leonova O.N., Stepanova E.V., Belyakov N.A. Severe and comorbid conditions in HIV patients: an analysis of adverse outcomes. HIV Infection and Immunosuppressive Disorders. 2017; 9 (1): 55–64. DOI: 10.22328/2077-9828-2017-9-1-55-64 (in Russ.).
  5. Lerner A.M., Eisinger R.W., Fauci A.S. Comorbidities in Persons With HIV: The Lingering Challenge. JAMA. 2020; 323 (1): 19–20. DOI: 10.1001/jama.2019.19775
  6. Smith C.J., Ryom L., Weber R., Morlat P., Pradier C., Reiss P. et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. Lancet. 2014; 384 (9939): 241–8. DOI: 10.1016/S0140- 6736(14)60604-8
  7. Triant V.A. Epidemiology of Coronary Heart Disease in HIV Patients. Rev. Cardiovasc. Med. 2014; 15 (1): S1–8.
  8. Barbaro G., Barbarini G. Human immunodeficiency virus & cardiovascular risk. The Indian Journal of Medical Research. 2011; 134: 6: 898–903. DOI: 10.4103/0971-5916.92634
  9. Hsue P.Y., Lo J.C., Franklin A., Bolger A.F., Martin J.N. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004; 109 (13): 1603–8. DOI: 10.1161/01.CIR. 0000124480.32233.8A
  10. Erqou S., Lodebo B.T., Masri A., Altibi A.M., Echouffo-Tcheugui J.B., DzudieA. et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis. JACC: Heart Failure. 2019; 7 (2): 98–108. DOI: 10.1016/ j.jchf.2018.10.006
  11. Barbaro G., Barbarini G., Pellicelli A.M. HIVassociated coronary arteritis in a patient with fatal myocardial infarction. N. Engl. J. Med. 2001; 344 (23): 1799–800. DOI: 10.1056/NEJM200106073442316
  12. Freiberg M.S., Chang C.C., Kuller L.H., Skanderson M., Lowy E., Kraemer K.L. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 2013; 173: 614–22. DOI: 10.1001/jamainternmed.2013.3728
  13. Currie P.F., Jacob A.J., Foreman A.R., Elton R.A., Brettle R.P., Boon N.A. Heart muscle disease related to HIV infection: prognostic implications. BMJ. 1994; 309: 6969: 1605–7.
  14. Zakharova N.G., Dvorak S.I., Guba Z.V., Plavinsky S.L., Rassokhin V.V., Belyakov N.A. et al. The causes of unfavorable outcomes among patients taking HAART. Part II. HIV Infection and Immunosuppressive Disorders. 2015; 7 (4): 52–63. DOI: 10.22328/2077-9828-2015-7-4-5-8 (in Russ.).
  15. Hsue P.Y., Waters D.D. Heart failure in persons living with HIV infection. Curr. Opin. HIV AIDS. 2017; 12 (6): 534–9. DOI: 10.1097/COH.0000000000000409
  16. Frieberg M.S., Chang C.H., Skanderson M. Association Between HIV Infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017; 2 (5): 536–46. DOI: 10.1001/jamacardio.2017.0264
  17. Goryacheva O.G., Koziolova N.A., Terekhina N.A. HIV-associated cardiovascular pathology. Russian Journal of Cardiology. 2019; 24 (11): 148–54. DOI: 10.15829/1560-4071-2019-11-148-154 (in Russ.).
  18. Yusuf S., Hawken S., Ôunpuu S., Dans T., Avezum A., Lanas F. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
  19. Tonen-Wolyec S., Bouassa R.S.M., Batina-Agasa S., Tepungipame A.T., Tshilumba C.K., Bélec L. et al. Sociodemographic characteristics of adolescents preferring home-based HIV self-testing over facility-based voluntary counseling and testing: a cross-sectional study in Kisangani, Democratic Republic of the Congo. International Journal of STD & AIDS. 2020. DOI: 10.1177/0956462419898616
  20. Silva A.G., Paulo R.V., Silva-Vergara M.L. Subclinical carotid atherosclerosis and reduced DAD Score for Cardiovascular Risk Stratification in HIV-Positive Patients. Arquivosbrasileiros de Cardiologia. 2019. AHEAD. DOI: 10.5935/abc.20190227
  21. Vorob’eva E.N., Shumakher G.I., Khoreva M.A., Osipova I.V. Endothelial dysfunction – a key factor in atherosclerosis pathogenesis. Russian Journal of Cardiology. 2010; (2): 84–91. DOI: 10.15829/1560-4071-2010-2-84-91 (in Russ.).
  22. Panhwar M.S., Mansoor E., Al-Kindi S.G., Sinh P., Katz J., Oliveira G.H. et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based national study. Inflammatory Bowel Diseases. 2019; 6 (25): 1080–7. DOI: 10.1093/ibd/izy354
  23. Barbaro G., Silva E.F.R. Cardiovascular complications in the acquired immunodeficiency syndrome. Revista da Associac, a~o Mйdica Brasileira. 2009; 55 (5): 621–30. DOI: 10.1590/S0104-42302009000500031
  24. Hatleberg C.I., Ryom L., El-Sadr W., Mocroft A., Reiss P., De Wit S. et al. Data Collection of Adverse Events of Anti-HIV Drugs (D: A: D) Study Group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D: A: D Study. JInt AIDS Soc. 2018; 21: e25083. DOI: 10.1002/jia2.25083
  25. Solomon D., Sabin C.A., Mallon P. Cardiovascular disease in women living with HIV: Anarrative review. Maturitas. 2018; 108: 58–70. DOI: 10.1016/j.maturitas.2017.11.012
  26. Raghavan A., Rimmelin D., Fitch K., Zanni M. Sex differences in select Non-communicable HIVassociated comorbidities: exploring the role of systemic immune activation/inflammation. Curr. HIV/AIDS Rep. 2017; 14 (6): 220–8. DOI: 10.1007/s11904-017-0366-8
  27. Glesby M.J., Hanna D.B., Hoover D.R., Pawinski R., Zeller K., Moodley P. et al. Abdominal fat depots and subclinical carotid artery atherosclerosis in women with and without HIV infection. J. Acquir. Immune Defic. Syndr. 2018; 77 (3): 308–16. DOI: 10.1097/QAI.0000000000001606
  28. Srinivasa S., Fitch K.V., Torriani M., Zanni M.V., Defilippi C., Christenson R. et al. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. Aids. 2019; 33 (2): 229–36. DOI: 10.1097/QAD.0000000000002060
  29. Gould K.L., Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. Am. J. Cardiol. 1974; 34 (1): 48–55. DOI: 10.1016/0002-9149(74)90092-7
  30. Levine G.N., Bates E.R., Bittl J.A., Brindis R.G., Fihn S.D., Fleisher L.A., Mehran R. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart. Circulation. 2016; 134 (10): e123–55. DOI: 10.1161/CIR.0000000000000404
  31. De Nardo D., Labzin L., Kono H., Seki R., Schmidt S.V., Beyer M., Vogelhuber J. High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3. National Immunology. 2014; 15 (2): 152–60. DOI: 10.1038/ni.2784
  32. Rose H., Hoy J., Woolley I., Tchoua U., Bukrinsky M., Dart A., Sviridov D. HIV infection and highdensity lipoprotein metabolism. Atherosclerosis. 2008; 199 (1): 79–86. DOI: 10.1016/j.atherosclerosis.2007.10.018
  33. Duprez D.A., Neuhaus J., Tracy R., Kuller L.H., Deeks S.G., Orkin C. et al. INSIGHT SMART Group. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIVinfected patients. AIDS. 2011; 25 (5): 651–7. DOI: 10.1097/QAD.0b013e32834404a1
  34. Post W.S., Budoff M., Kingsley L., Palella, F.J., Jr., Witt M.D., Li X., Jacobson L.P. Associations between HIV infection and subclinical coronary atherosclerosis. Ann. Intern. Med. 2014; 160 (7): 458–67. DOI: 10.7326/M13-1754
  35. Salmazo P.S., Bazan S.G.Z., Shiraishi F.G., Bazan R., Okoshi K., Hueb J.C. Frequency of Subclinical Atherosclerosis in Brazilian HIV-Infected Patients. Arq. Bras. Cardiol. 2018; 110 (5): 402–10. DOI: 10.5935/ abc.20180058
  36. Muccini C., Galli L., Poli A., Carbone A., Maillard M., Giusti M.C., Lazzarin A. Hyperbilirubinemia is associated with a decreased risk of carotid atherosclerosis in HIV-infected patients on virological suppression. J. Acquir. Immune Defic. Syndr. 2018; 79 (5): 617–23. DOI: 10.1097/QAI.0000000000001854
  37. Pillay B., Ramdial P.K., Naidoo D.P., Sartorius B., Singh D. Endovascular therapy for large vessel vasculopathy in HIV-infected patients. Eur. J. Vasc. Endovasc. Surg. 2016; 52 (3): 343–51. DOI: 10.1016/j.ejvs.2016.06.007
  38. Cerrato E., D’Ascenzo F., Biondi-Zoccai G., Calcagno A., Frea S., Grosso Marra W., Presutti D. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur. Heart J. 2013; 34 (19): 1432–6. DOI: 10.1093/eurheartj/ehs471
  39. Boccara F., Basilua J.M., Mary-Krause M., Lang S., Teiger E., Steg P.G. et al. PACS-HIV Investigators (Prognosis of Acute Coronary Syndrome in HIV-infected patients). Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: results from the PACS-HIV lipids substudy. Am Heart. J. 2017; 183: 91–101. DOI: 10.1016/j.ahj.2016.10.013
  40. DeFilippi С., Christenson R., Joyce J. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. J. Acquir. Immune Defic. Syndr. 2018; 78 (1): 105–110. DOI: 10.1097/QAI.0000000000001644
  41. McGill H.C., Jr., McMahan C.A., Zieske A.W., Tracy R.E., Malcom G.T., Herderick E.E. et al. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000; 102 (4): 374–9.DOI: 10.1161/01.CIR.102.4.374
  42. Okazaki S., Sakaguchi M., Miwa K., Furukado S., Yamagami H., Yagita Y. et al. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. Stroke. 2014; 45 (10): 2924–9. DOI: 10.1161/STROKEAHA.114.005991
  43. Kholodnaya A.N., Lioznov D.A., Nikolaenko S.L., Blokhina E.A., Yaroslavtseva T.S., Krupitskiy E.M. Assessment of systemic inflammation markers in HIV infected opiate users. HIV Infection and ImmunosuppressiveDisorders. 2018; 10 (2): 90–5. DOI: 10.22328/2077-9828-2018-10-2-90-95 (in Russ.).
  44. Mudritskaya T.N., Turna E.Yu., Zakharova M.A., Grigorenko E.I. The lesion of the cardiovascular system in HIV infection. Crimean Journal of Internal Diseases. 2014; 2: 82–88. (in Russ.).
  45. Barrett T.J. Macrophages in atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 2020; 40 (1): 20–33. DOI: 10.1161/ATVBAHA.119.312802
  46. Tajbakhsh A., Kovanen P.T., Rezaee M., Banach M., Moallem S.A., Sahebkar A. Regulation of efferocytosis by caspase-dependent apoptotic cell death in atherosclerosis. Internat. J. Biochem. & Cell Biol. 2020; 120: 105684. DOI: 10.1016/j.biocel.2020.105684
  47. Doitsh G., Cavrois M., Lassen K.G., Zepeda O., Yang Z., Santiago M.L., Greene W.C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010; 143 (5): 789–801. DOI: 10.1016/j.cell.2010.11.001
  48. Lamkanfi M., Dixit V. Mechanisms and functions of inflammasomes. Cell. 2014; 157 (5): 1013–22. DOI: 10.1016/j.cell.2014.04.007
  49. Vartanyan A.A., Kosorukov V.S. Pyroptosis as inflammatory cell death. Clinical Oncohematology. 2020; 13 (2): 129–35. DOI: 10.21320/2500-2139-2020-13-2-129-135 (in Russ.).
  50. Yuan Y.Y., Xie K.X., Wang S.L., Yuan L.W. Inflammatory caspase-related pyroptosis: mechanism, regulation and therapeutic potential for inflammatory bowel disease. Gastroenterol. Rep. 2018; 6 (3): 167–76. DOI: 10.1093/gastro/goy011
  51. Kesavardhana S., Malireddi R.K.S., Kanneganti T.D. Caspases in cell death, inflammation, and pyroptosis. Ann. Rev. Immunol. 2020; 38: 567–95. DOI: 10.1146/annurev-immunol-073119-095439
  52. Miranda Pérez A.A., Gutiérrez Pérez M.E., Urraza Robledo A.I., Delgadillo Guzmán D., Ruíz Flores P., López Márquez F.C. Klotho-HIV and Oxidative Stress: The Role of Klotho in Cardiovascular Disease Under HIV Infection – A Review. DNA Cell. Biol. 2020. DOI: 10.1089/dna.2020.5444
  53. Martínez-Ayala P., Alanis-Sánchez G.A., Gonzalez-Hernández L.A., Álvarez-Zavala M., Cabrera-Silva R.I., Andrade-Villanueva J.F., et al. Aortic stiffness and central hemodynamics in treatment naive HIV infection: A cross-sectional study.2020.
  54. Kearns A., Gordon J., Burdo T.H., Qin X. HIV-1–associated atherosclerosis: unraveling the missing link. J. Am. Coll. Cardiol. 2017; 69 (25): 3084–98. DOI: 10.1016/j.jacc.2017.05.012
  55. Yang K., Chi H. Autophagy modulates CD4+ Tcell lineage recommitment upon pathogen infection. Cell. Mol. Immunol. 2020; 17: 682–3. DOI: 10.1038/s41423-020-0368-0
  56. Freidlin I.S., Mammedova Dzh.T., Starikova E.A. The Role of autophagy in infections. Russian Journal of Physiology. 2019; 105 (12): 1486–501. DOI: 10.1134/S0869813919120057 (in Russ.).
  57. Kooij K.W., Schouten J., Wit F.W., van der Valk M., Kootstra N.A., Stolte I.G. et al. Difference in aortic stiffness between treated middle-aged hiv type 1–infected and uninfected individuals largely explained by traditional cardiovascular risk factors, with an additional contribution of prior advanced immunodeficiency. J. Acquir. Immune Defic. Syndr. 2016; 73 (1): 55–62. DOI: 10.1097/QAI.0000000000001024
  58. Shmagel K.V. Discordant response of CD4+ T lymphocytes to antiretroviral therapy. HIV Infection and Immunosuppressive Disorders. 2019; 11 (1): 16–30. DOI: 10.22328/2077-9828-2019-11-1-16-30 (in Russ.).
  59. Abner A., Arrigoni F., Luckhurst N., Tinago W., Walker A.S., Heyderman R.S. et al. Inflammatory phenotypes predict changes in arterial stiffness following ART initiation. Clinical Infectious Diseases. 2020. DOI: 10.1093/cid/ciaa186
  60. Schneider S., Spinner C.D., Cassese S., Promny D., Hapfelmeier A., Byrne R.A., Kastrati A. Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. AIDS. 2016; 30: 1413–21. DOI: 10.1097/QAD.0000000000001063
  61. Lederman M.M., Margolis L. The lymph node in HIV pathogenesis. Semin Immunol. 2008; 20 (3): 187–95. DOI: 10.1016/j.smim.2008.06.001
  62. Herbein G., Varin A. The macrophage in HIV-1 infection: from activation to deactivation? Retrovir. 2010; 7: 33. DOI: 10.1186/1742-4690-7-33
  63. Sanchez-Rodriguez E., Egea-Zorrilla A., Plaza-Díaz J., Aragón-Vela J., Mun~oz-Quezada S., Tercedor-Sánchez L. et al. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients. 2020; 12 (3): 605. DOI: 10.3390/nu12030605
  64. Gogokhia L., Taur Y., Juluru K., Yagan N., Zhu Y.S., Pamer E., Glesby M.J. Intestinal dysbiosis and markers of systemic inflammation in viscerally and generally obese persons living with HIV. J. Acquir. Immune Defic. Syndr. 2020; 83 (1): 81–9. DOI: 10.1097/QAI.0000000000002229
  65. Barbaro G. Heart and HAART: Two sides of the coin for HIV associated cardiology issues. World J. Cardiol. 2010; 2 (3): 53–7. DOI: 10.4330/wjc.v2.i3.53
  66. Oliveira G.H. Novel serologic markers of cardiovascular risk. Curr. Atheroscler. Rep. 2005; 7 (2): 148–54. DOI: 10.1007/s11883-005-0038-9
  67. Friis-Moller N., Sabin C.A., Weber R., D'Arminio Monforte A., De Wit S. et al. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 2003; 349: 1993–2003
  68. Pogosova G.V., Tikhomirova L.A. Depressive disorders and cardiovascular diseases. Disease Prevention and Health Promotion. 2004; 3: 10–3 (in Russ.).
  69. Galea J.T., Marhefka S., Cyrus E., Contreras C., Brown B. Novel approach to scale integrated depression and HIV care. Lancet. HIV. 2020. DOI: 10.1016/S2352-3018(20)30025-4

About Authors

  • Ilkhom T. Murkamilov, Cand. Med. Sc., Acting Associate Professor, ORCID
  • Kubanych A. Aytbaev, Dr. Med. Sc., Professor, Head of Laboratory, ORCID
  • Viktor V. Fomin, Dr. Med. Sc., Professor, Corresponding Member of RAS, Chief of Chair, Vice-Rector, ORCID
  • Andrey I. Schastlivenko, Cand. Med. Sc., Associate Professor, ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by